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Introduction
Approximately one-third of patients with RCC3 have metastatic
disease at initial presentation or on relapse, and the prognosis for 
metastatic RCC remains highly unfavorable, because RCC is usually 
resistant to radiotherapy and chemotherapy. Therefore, new treatment 
modalities including novel immunotherapeutic approaches are being 
investigated and are promising.
rIL-2 is currently the only immunotherapeutic agent approved for 
use in RCC by the United States Food and Drug Administration and 
is the current gold standard for treating metastatic RCC. Treatment 
with high-dose i.v. bolus rIL-2 regimens produces objective response 
rates of approximately 20%, and the majority of complete responses 
are durable for 3 or more years. Immunotherapy with rIL-2 has 
produced significant improvements in long-term survival and has led 
to the investigation of a variety of other immunotherapeutic ap­
proaches for treating metastatic RCC.
At a recent symposium held in September 1996 in Washington,
D.C. and sponsored by the National Cancer Institute, clinicians and 
researchers convened to discuss recent progress and future directions 
in the diagnosis and treatment of RCC. Presentations focused on two 
areas of active research: (a) understanding the molecular genetics and 
biology of RCC; and (b) new immunotherapeutic strategies. Recent 
developments in these areas are generating a great deal of enthusiasm. 
Several genes have recently been identified that may contribute to the 
development of several hereditary forms of RCC. Identification of 
these genes may lead to improved screening tests and new therapeutic 
options. Advances in immunotherapy for RCC are also exciting. New 
combination regimens, adoptive immunotherapy, gene therapy, and 
therapeutic mAbs are currently being investigated, and many of these 
approaches are showing promise. Other areas of research, including 
multidrug resistance and host factors that influence the antitumor 
immune response, were also discussed.
Epidemiology. In recent years, the incidence of RCC has increased 
dramatically (54% from 1975 to 1990), and in 1996, approximately 
30,000 new cases were diagnosed in the United States (1). In the same 
year, an estimated 12,000 RCC-related deaths occurred in the United 
States (2). The increased incidence of RCC in recent years may be 
linked to certain risk factors such as smoking, obesity, high-protein 
diets, and hypertension (3). For example, smoking is associated with 
a 40% increased risk. Hypertension, with the associated use of diuret­
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ics and antihypertensive drugs, is also associated with a slightly 
increased risk of RCC (4, 5).
Nearly half of all RCC patients present with localized disease, 
one-quarter present with stage III disease, and nearly one-third of 
patients present with metastatic disease (1). In addition, as many as 
40% of all patients treated for local tumors will ultimately relapse 
with metastatic disease (6). The prognosis of untreated patients with 
metastatic disease is unfavorable, with a 3-year survival rate of less 
than 5% (7). Among patients who develop metastases within 1 year of 
nephrectomy, the 2-year survival rate is likewise very poor. In a few 
rare cases, however, in which patients develop metastases more than
2 years postnephrectomy, long-term survival in excess of 5 years has 
been observed (8).
Pathology. The majority of RCC tumors have a distinct clear cell 
histology; however, approximately 25% of cases exhibit a mixed 
histology (9). The Mainz classification system defines clear, chro- 
mophilic, and chromophobic histological types as distinct morpholo­
gies with clearly distinguishable cellular, enzymatic, and genetic 
characteristics (10). The importance of diagnosing and appropriately 
treating multifocal disease has also been addressed. Multifocal disease 
is associated with an increased incidence of papillary and mixed 
histologies.
Molecular Genetics. Several tumor suppressor genes, including 
the VHL gene, the WTJ gene, and the tuberous sclerosis gene 2, have 
been implicated in the development of sporadic as well as hereditary 
tumors in the kidney. The WT1 tumor suppressor gene may regulate 
the activity of two key oncogenes, hcl-2 and c-myc, that may contrib­
ute to the development of RCC ( 11). Key genetic components in the 
pathogenesis of RCC will likely be identified through studies involv­
ing the Eker rat model of hereditary predisposition to RCC. Several 
participants also presented evidence of increased telomerase activity 
in RCC relative to normal renal tissue, suggesting that this enzyme 
may play a role in the pathogenesis of RCC and could serve as a 
useful diagnostic marker.
To identify genes involved in the origin of clear cell RCC, studies 
were performed of a hereditary form of clear cell RCC associated with 
VHL VHL disease is a hereditary cancer syndrome in which affected 
individuals are at risk for the development of tumors in the kidney, 
adrenal, pancreas, cerebellum, spine, inner ear, retina, and epididymis. 
VHL patients can develop bilateral multifocal renal tumors and cysts, 
which can appear at an early age (12). The renal tumors that develop 
in VHL patients are uniformly of clear cell type (13). Genetic linkage 
analysis identified the VHL gene, which is located on the short arm of 
chromosome 3 (14). The VHL gene has been found to have the 
characteristics of a classic tumor suppressor gene. In tumors from 
patients with VHL, both copies of the VHL gene are inactivated, one 
copy by germ-line mutation and the other by loss of heterozygosity. 
The VHL wild-type allele is lost early in the development of VHL 
renal lesions (15). To determine if the VHL gene is associated with 
sporadic renal tumors, VHL gene mutation and loss of heterozygosity 
analysis was performed on cell lines and tumors from patients with 
nonhereditary, clear cell RCC. VHL gene mutations and loss of
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heterozygosity were found in a high percentage of clear cell RCCs 
(16, 17). Additionally, Herman et ciL (18) have shown that hyper- 
methylation of the normally unmethylated CpG island of the 5' region 
of the VH L  gene provides another mechanism for inactivation or 
silencing of the VHL tumor suppressor gene in clear cell RCC.
In a study of the function of the VHL protein, Lee et a l  (19) have 
shown that there is a tightly regulated cell density-dependent transport 
of VHL into and out of the nucleus. The VHL protein is found to be 
predominantly in the nucleus of cells grown under sparse conditions. 
When the cells are densely grown, the VHL protein is mostly in the 
cytoplasm (19). Studies of VHL-associated proteins have provided 
critical insights into the potential function of the VHL kidney cancer 
tumor suppressor gene. Duan et a l  (20) and Kibel et al. (21) have 
shown that the cellular transcription factor, Elongin (SIII), is a target 
of the VHL protein. The VHL protein binds specifically and tightly to 
the Elongin B and C regulatory subunits of the Elongin A,B,C 
heterotrimer that activates transcription elongation by RNA polymer­
ase II (20, 21). Pause et a l  (22) have recently shown the trimeric 
pVHL-elongin B-C complex associates with Hs-CUL-2, a member of 
the cullin multigene family (22). The finding that the yeast homologue 
of Hs-CUL-2, Cdc53, targets cell cycle proteins for degradation has 
suggested additional studies to determine the potential role of VHL in 
cell cycle regulation. Additional functional studies of the VHL gene 
have investigated its role in regulation of VEGF. Both sporadic clear 
cell RCC and the tumors associated with VHL are markedly vascular. 
Many of these tumors express high levels of VEGF. The VHL protein 
has been found to be a negative regulator of the hypoxia-inducible 
genes, including VEGF. The VHL protein can regulate VEGF expres­
sion at a posttranscriptional level. It has been shown that inactivation 
of VHL can be associated with a loss of VEGF suppression, which 
may play a role in the formation of tumor-associated angiogenesis 
(23, 24).
A new form of hereditary RCC, HPRC, has recently been described 
(25, 26). Affected individuals are at risk to develop multifocal bilat­
eral papillary RCC. HPRC is distinct from VHL; patients do not 
develop the clinical manifestations of VHL, and germ-line VHL gene 
mutations are not found. Schmidt et aL (27) localized the H P R C  gene 
to a region on the long arm of chromosome 7. Using a positional 
mapping approach, the M E T  proto-oncogene was identified as a 
strong candidate for the H P R C  gene. In the germ-line of affected 
HPRC individuals, missense mutations located in the tyrosine kinase 
domain of the M E T  gene were identified (27). Additional studies are 
underway to more accurately determine the phenotype of HPRC and 
to determine if other malignancies are associated with this hereditary 
cancer syndrome.
Therapeutic Challenges
A major challenge to the development of effective therapies for the 
treatment of metastatic RCC is its resistance to both chemotherapy 
and radiotherapy. RCCs typically exhibit a multi drug-resistant phe­
notype associated with expression of the multidrug resistance gene 
(MDR-J; Ref. 28), and objective responses to chemotherapy occur in 
<10% of treated patients (29). However, RCC is known to be immu­
nogenic, and immunotherapy. with biological response modifiers has 
had some measure of success. Indeed, significant clinical responses 
have been achieved with rIL-2, which is currently the standard therapy 
for metastatic RCC patients with good performance status (30). Al­
though rIL-2 has no direct cytotoxic antitumor effect, its widely 
documented inhibitory effect on the growth of human cancers, includ­
ing colon carcinoma, bladder carcinoma, and melanoma^ stems from 
its ability to activate an antitumor immune response (31).
With the success of rIL-2 therapy, and based on the pioneering
work of Dr. Steven Rosenberg, in metastatic melanoma and RCC at 
the National Cancer Institute, a variety of approaches to immunother­
apy are being investigated for the treatment of metastatic RCC. These 
include (a) immunomodulation with biological response modifiers; 
{b) adoptive immunotherapy, which involves the transfer of cells with 
antitumor activity; (c) therapeutic tumor-specific mAbs; (d) vaccines 
designed to stimulate a specific antitumor immune response; and (e) 
gene therapy. Current and future preclinical and clinical research on 
immunotherapy for metastatic RCC are summarized in Tables 1 and 2.
Biological Response Modifiers
rIL-2. rIL-2 obtained United States Food and Drug Administration 
approval in 1992 on the basis of demonstrated safety and efficacy in 
clinical studies involving 255 patients with RCC who were treated 
with high-dose rIL-2 regimens (55). The cumulative experience with 
high-dose rIL-2 therapy has demonstrated approximately a 15% ob­
jective response rate (complete and partial responses), mostly in 
patients with good clinical performance status, with a median survival 
of approximately 40 months for patients achieving a complete re­
sponse and 24 months for patients achieving a partial response, The 
objective response rate for RCC patients treated at the National 
Cancer Institute with high-dose i.v. bolus rIL-2 before December 
1992 was 20% (56). More than 75% of patients achieving a complete 
response remained disease free for 3+  years, and some complete 
responses have been durable for 5+ years. The major challenge has 
been to develop new regimens and new strategies to further improve 
survival with manageable toxicity.
Dr. James C. Yang, presented results involving 260 patients in an 
ongoing three-armed randomized trial designed to establish the opti­
mum dose of rIL-2. This trial compared 720,000 IU/kg i.v, bolus 
every 8 h (high-dose i.v. bolus group), 72,000 IU/kg i.v. bolus every 
8 h (low-dose i.v. bolus group), and 120,000 IU/day s.c. for 5 days 
each week (s.c. group; 40). The objective response rates were 21% in 
the high-dose i.v. bolus group compared with only 11% in the low- 
dose i.v. bolus group, and response durations were significantly longer 
in the high-dose group. Toxicity, including hypotension, dyspnea, 
thrombocytopenia, malaise, and disorientation, was significantly 
greater with the high-dose regimen, and approximately 50% of pa­
tients in this group required treatment for hypotension compared with 
less than 5% in the low-dose group. The response rate and toxicities 
observed in the s.c. group were similar to those observed in the 
low-dose i.v. bolus group, Although the high-dose i.v. bolus regimen 
is associated with significant toxicity, it seems to be the most effective 
rIL-2 regimen in terms of response rate, duration of response, and 
overall survival, With adequate monitoring of patients, it can be 
tolerated without risk of treatment-related mortality.
Dr. Janice Dutcher addressed the role of nephrectomy in selected 
patients who responded to rIL-2 treatment. In a study reported by 
Bennett et al. (57), four of six patients whose renal tumors progressed 
after immunotherapy exhibited no evidence of residual disease after 
resection and have remained disease free for nearly 5 years.
Table 1 Preclinical research in metastatic RC C
Immunotherapeutic agent Result Ref.
Biological response modifiers
IL-2 plus IL-12 Delayed tumor growth (murine 32
model)
Adoptive immunotherapy
Dendritic cells May induce RCC-specific immune 33
response, CTL activation, 34
cytokine production 35
Tumor-specific vaccines Identification o f  RCC-specific 36
antigens: G250 and renal tumor 37




Table 2 Clinical research in m etastatic R C C
Immunotherapeutic agent Therapy Overall response rate Ref.
Biological response modifiers 
rIL-2 720,000 IU/kg (high-dose i.v. bolus) 2 1 % 40
rIF N -a 10-20 M IU /m 2/day 18% 41
IF N -a  plus CRA 3 -9  MIU rIFN -a; I mg/kg/day C R A 30% 42
rIFN -y 60-100  /xg (s.c., IX /w k) 15% 43
rlL-2 plus rIFN -a W ith chemotherapy U p lo 47%
44
45




TILs rIL-2 and TILs 12% 48
rIL-2, IFN -a, and TILs 35% 49
A LT 6  monthly leukocyte infusions 2.5 X survival tim e 50
Priming tumor-specific CTLs CTLs reinfused into patient 2 C R " and 2 P R ;* N  =  12 51
Gene therapy
Genetically modified tum or cells GM -CSF-secreting tum or cell infusion 4 X D T H *7 response 52
Intralesional gene therapy Gene transfer via intratumoral injection 
1 *1 1 N one; safety  approved 53
mAbs I-labeled G250 antibody 2 0 %  PR 54
" CR, complete response,
h PR, partial response.
c DTH, delayed-type hypersensitivity.
The acceptance of rIL-2 as the standard therapy for metastatic RCC 
has led.to the investigation of other biological response modifiers for 
treating this disease. These include rIFN-a, rlFN-y, and rIL-12, alone 
or combined with other agents such as CRA or adoptive immuno­
therapy .
rIFN -a. Since the first clinical trials in 1983 suggesting that 
rIFN-a was effective in metastatic RCC, a large number of studies 
have been conducted, The objective response rate from the treatment 
of more than 900 patients in 13 clinical trials with rIFN-a; was 18.4%, 
and response durations ranged from 6-10  months; however, complete 
responses are rare (30, 33, 49), Despite the large number of studies 
investigating the efficacy of rIFN-a in metastatic RCC, the optimal 
dose and schedule have not been determined because of significant 
variability in reported response rates, which may stem from differ­
ences in regimens and patient populations. The published data do 
suggest, however, that a dose of 10-20 MlU/day produces optimal 
response rates with single-agent rIFN-a therapy (41). The impact of 
single-agent rIFN-a on overall survival has not been determined.
Certain variables seem to predict the likelihood of response to 
rIFN-a therapy, Patients with a good performance status, prior ne­
phrectomy, and nonbulky pulmonary and/or soft tissue metastases 
who are asymptomatic or exhibit minimal symptoms have a higher 
likelihood of response. Indeed, response rates of up to 30% and 
response durations of >27 months have been observed in a select 
subset of patients (58, 59). These patients had prior nephrectomy, 
good-to-excellent performance status, and no previous chemotherapy 
or radiotherapy. In contrast, patients with un resec ted primary RCC, 
extensive prior treatment, and bulky metastases to viscera or bone 
were less likely to respond (60), An ongoing Southwest Oncology 
Group study is comparing rIFN-a therapy with and without prior 
nephrectomy to determine whether nephrectomy can improve re­
sponse to immunotherapy (30).
IFN -a Plus CRA. A promising combination regimen that has 
demonstrated synergistic antitumor effects in vitro against several 
RCC cell lines is the combination of liFN-o: with CRA. Dr. Robert 
Motzer presented the results of a recent Phase II trial in which 44 RCC 
patients were treated with 3-9 MlU/day rIFN-a:2a plus 1 mg/kg/day 
CRA (42). Thirteen of 43 evaluable patients (30%) achieved an 
objective response (3 complete responses and 10 partial responses), 
and the median response duration was 22 months. The results of this 
study suggested that this combination regimen may have additive 
therapeutic benefit compared with rIFN-a alone. The Eastern Coop­
erative Oncology Group has initiated a randomized Phase III trial to 
directly compare the effect of rIFN-a; alone with rIFN-a plus CRA.
rIF N -7 . The efficacy of rIFN-7  in metastatic RCC has only re­
cently been investigated. Dr. Eric Small presented two studies that 
were based on the results of a randomized Phase II trial of a low-dose 
regimen (100 yxg/week s.c.), which produced an objective response 
rate of 15% (43). A United States Cooperative Group randomized, 
open-lab el trial investigated the efficacy of 100 |u,g/m2/day s.c. in 200 
patients who had undergone prior nephrectomy or embolization (44). 
The overall response rate in this study was only 3%; however, this 
dose of rIFN-7  was well tolerated. A similar study conducted in 
Canada failed to demonstrate any clinical benefit of rIFN-7  therapy. 
Results of this study will be published in the near future.
Combination T herapy  W ith  rlFN-o? and  rIL-2. Preclinical mu­
rine tumor models have demonstrated synergistic antitumor effects 
with the combination of rIFN-a and rIL-2, establishing a compelling 
rationale for their combined use (61). The mechanisms of synergy are 
unclear, but administration of rIFN -a may augment the immunoge- 
nicity of tumor cells by enhancing expression of MHC antigens and 
presentation of tumor-associated antigens to T  lymphocytes.
Clinical trials have established the safety and efficacy of combina­
tion therapy with rIFN-a and rIL-2 in metastatic RCC. The available 
data from 1200 patients treated with this combination collectively 
demonstrate an objective response rale of approximately 20%, and 
approximately 5% of patients achieved a complete response. Re­
sponses overall have occurred at all disease sites, including bone, 
intact primary tumors, and visceral metastases, and have included 
patients with large tumor burdens or bulky individual lesions. Some 
durable complete responses have been observed. The frequency of 
response with this combination is equivalent to or greater than that 
reported with rIL-2 alone, and durable complete responses are re­
ported with both regimens; however, no large randomized trial has 
directly compared the efficacy of rIL-2 alone versus rIL-2 plus 
rIFN-a.
Several studies have also investigated the combination of rIL-2, 
rIFN-a, and 5-fluorouracil for metastatic RCC, with encouraging 
results (46, 47). In a Phase II outpatient study investigating the 
efficacy of s.c. rIL-2 (20 M IU/m 2) and rIFN-a: (6 -9  MIU/m2) plus i.v. 
bolus 5-fluorouracil (750 mg/m2), an overall response rate of 39% was 
observed (11% complete responses and 28% partial responses) (45). 
Stratification of patients by risk factors disclosed a significant survival 
advantage with this combination compared with single-agent rIL-2 in
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low- and intermediate-risk patients. Others have reported similarly 
encouraging results, with an objective response rate of 47% (46), 
Confirmation of these efficacy data and additional information about 
the toxicity associated with this regimen are needed.
rIL«12. Preclinical and Phase 1 clinical trials are currently inves-
tigating the biological effects of rIL-12 and its antitumor activity in 
metastatic RCC. IL-12 is thought to induce expression of other cyto­
kines and chemokines. Preclinical experiments conducted by Dr. Jon 
Wigginton et al. have shown that administration of weekly pulses of 
rIL-2 in combination with rIL-12 additively enhanced the priming of 
macrophages for nitric oxide production in culture and reversed tumor 
growth in mice far more effectively than did either agent alone (32). 
Dr. Robert Wiltrout also speculated that the combination of rIL-2 plus 
rIL-12 may induce some antiangiogenic effects.
Dr. Ronald M. Bukowski presented interim data from two ongoing 
Phase I clinical trials investigating the safety and effectiveness of 
rIL-12 in metastatic RCC. The first trial is investigating a fixed dose 
ol s.c. rIL-12 (ranging from 0.1 to 1 jmg/kg), and the second is a 
do ;e-escalation trial starting at 0.1 /xg/kg and escalating to the max­
im. im tolerated dose, which has not yet been reached. Tumor regres- 
sioi i has not yet been observed in these studies, but some changes in 
rates of tumor growth have been documented. In 50% of patients, an 
induction of IFN-y RNA was observed. In addition, two IFN-induc- 
ible chemokines were detected in rIL-12-treated patients, suggesting 
that rIL-12 induces IFN-y expression, resulting in an enhanced anti­
tumor immune response.
Adoptive Immunotherapy
A variety of adoptive immunotherapeutic approaches have been 
investigated in RCC, including adoptive transfer of TILs, lympho- 
kine-activated killer cells, and ALT. Lymphocytes with potential 
cytotoxic antitumor activity can be isolated from peripheral blood, 
tumor-draining lymph nodes, or tumor tissue. These cells are subse­
quently expanded ex vivo and reinfused into the patient, often in 
combination with biological response modifiers, with the hope of 
improving the rate and durability of response.
TILs. TILs can be isolated from the patient’s tumor, expanded ex 
vivo in rIL-2, and reinfused, typically in conjunction with rIL-2 and/or 
rIFN-a therapy or chemotherapy. In an early study, 12% of RCC 
patients treated with rIL-2 plus TILs achieved a clinical response (48). 
The University of California at Los Angeles experience with these 
regimens has been more favorable according to Dr. Arie Belldegrun. 
Of the 55 patients treated with a combination of rIFN~a priming, 
TILs, and low-dose i.v. rIL-2, 35% achieved a clinical response (9% 
complete responses and 25% partial responses) with no significant 
toxicity (49). Among those patients who responded to therapy, 43% 
survived 2 +  years. Median survival among patients achieving a 
complete response was 42+  months. High baseline levels of circu­
lating natural killer cells were the only prognostic factor that corre­
lated with response. These results demonstrate that immunotherapy in 
combination with radical nephrectomy and adoptive transfer of TILs 
can provide substantial therapeutic benefit. Combined therapy with 
rIL-2, rIFN-a, and TILs has become the standard at the University of 
California at Los Angeles.
ALT. ALT refers to adoptive immunotherapy with autologous 
activated memory T lymphocytes that have been expanded and acti­
vated ex vivo. T lymphocytes are selected from peripheral blood 
leukocytes with anti~CD3 mAbs and then further enriched for acti­
vated memory T lymphocytes that have presumably been exposed to 
tumor antigens. These memory T cells are then expanded and non- 
specifically stimulated with cytokines to increase their cytolytic ac­
tivity and multicytokine secretion. The resulting cell population pre­
sumably contains activated CTLs with potential antitumor activity. 
Early studies suggested that ALT in combination with cimetidine (an 
agent postulated to inhibit suppressor T-cell activity) produced a
survival benefit (30).
To assess the clinical benefit of ALT in metastatic RCC, Dr.
Michael Hawkins et al. randomized 90 patients to receive cimetidine 
monthly for 6 months, alone, or in combination with ALT (50). 
Median survival in the ALT group was > 2  times longer (17 months) 
than in the group receiving cimetidine alone, a significant improve­
ment. Ten of 45 patients (22%) survived 44H- months, and toxicity 
associated with ALT was minimal. A Phase III trial in which patients 
are randomized to rlFN-o: plus cimetidine with or without ALT is
currently underway.
Priming Tumor-specific CTLs, Animal models have shown that 
adoptive immunotherapy can be effective against advanced malignan­
cies when lymphocytes derived from tumor-draining lymph nodes are 
primed with Covynebacterium pannim ex vivo and subsequently re­
infused. Dr. Alfred Chang described clinical experiments involving 
patients with melanoma or RCC in which a portion of each patient’s 
tumor mass was excised and used to prime tumor-specific CTLs. 
Tumor cells were irradiated and mixed with T lymphocytes from 
draining lymph nodes that had been stimulated in culture with bacillus 
Calmette-Guerin, By doing so, it was hoped that tumor-specific CTLs 
would proliferate in culture. As many as 10u cells, primarily CTLs, 
could then be reinfused into the patient. These cells demonstrate 
autologous antitumor cytolytic activity in vitro and have high GM- 
CSF and IFN-y cytokine profiles, both of which are important for 
T-cell-mediated immune reactivity (62). In a recent clinical trial 
involving 12 patients with RCC, 2 complete responses and 2 partial 
responses were obtained with this treatment (51).
Dendritic Cells. Dendritic cells represent yet another potential tool 
for generating supercharged tumor-specific CTLs in culture. These 
potent antigen-presenting cells, found in bone marrow, lymph nodes, 
spleen, and skin, can now be propagated from peripheral blood 
mononuclear cells in cultures containing hematopoietic growth factors 
such as GM-CSF and rIL-4 (34). Dendritic cells express high levels of 
MHC class I and II antigens as well as a variety of cell surface 
costimulatory and adhesion molecules. Consequently, they present 
antigens effectively to T lymphocytes (63). In addition, dendritic cells 
produce some cytokines, including rIL~12 (35). Research in mela­
noma and prostate cancer has demonstrated the potential usefulness of 
dendritic cell cultures for generating an antitumor cellular immune 
response (64-66). Dendritic cells can be pulsed with tumor-specific 
peptide antigens, whole proteins, or RNA-encoding peptide antigens. 
Ongoing research is investigating the use of dendritic cells from 
cancer patients to optimize tumor antigen presentation in culture and 
to increase production of tumor-specific CTLs. Preliminary data pre­
sented by Dr. Peter Mulders indicate that this approach is applicable 
to the therapeutic induction of an RCC-specific immune response
(33).
Gene Therapy
Genetically Engineered Tumor Ceils. In an effort to stimulate a 
more potent antitumor immune response, researchers are experiment- 
ing with methods of increasing the immunogenicity of tumor cells in 
melanoma and RCC. One approach involves the introduction of MHC 
class I or cytokine genes into tumor cells to enhance tumor antigen 
presentation and activation of tumor-specific CTLs (67). Genetically 
engineered tumor cells can be irradiated and reinfused into the patient, 
where they will function as a vaccine.
Murine studies have demonstrated that GM-CSF is a potent stim­
ulator of systemic antitumor immune responses (68). These findings
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have led to preclinical and clinical trials investigating the effective­
ness of RCC cells genetically engineered to express GM-CSF in 
generating an anti-RCC immune response. This type of tumor cell 
vaccine has induced complete eradication of established tumors in 
mice. Dr. Jonathan W. Simons described a clinical study in which 
several RCC patients were injected with increasing numbers of GM- 
CSF-secreting tumor cells. An early infiltration of mononuclear cells 
(especially macrophages and dendritic cells) at the vaccination site 
and an increased delayed-type hypersensitivity response were ob­
served in patients injected with untransfected and GM-CSF-trans- 
fected tumor cells. However, two of three patients injected with 
GM-CSF-secreting tumor cells exhibited a fourfold increase in the 
magnitude of the delayed-type hypersensitivity response compared 
with controls, and there was no evidence of toxicity (52). Further­
more, one of these patients exhibited a partial response to the vaccine. 
These results suggest that adoptive transfer of GM-CSF-secreting 
tumor cells may stimulate an effective antitumor response. Unfortu­
nately, this methodology is expensive and labor intensive, which may 
limit its clinical application.
Intralesional Gene Therapy. The direct transfer of genes encod­
ing MHC class I proteins or cytokines into tumor cells in vivo is a 
novel approach to enhancing the anti tumor cellular immune response, 
as described by Dr. Alain Schreiber. One advantage of direct in vivo 
transfer of DNA into tumor cells compared with ex vivo transfer is the 
simplicity of the procedure, which does not require expensive and 
time-consuming manipulation of tumor cells in culture. One disad­
vantage may be the low efficiency of gene transfer. In vivo transfer of 
cytokine genes has been shown to reduce tumor growth in the 
RENCA murine model (69). The first Phase I clinical trial of in vivo 
intralesional gene transfer used cationic liposomes to deliver a plas­
mid harboring the IL-2 gene. No objective responses were observed; 
however, the procedure was demonstrated to be safe. The results of a 
dose-optimization trial are still pending.
Similar Phase I trials are currently underway to examine direct gene 
transfer of the HLA-B7 gene and the /32 microglobulin gene (70), The 
HLA-B7 gene was chosen for these studies because of evidence that it 
is involved in presentation of tumor-specific antigens in melanoma 
and RCC. Direct intralesional transfer of die HLA-B7 gene into 
melanoma tumors has produced clinical responses in some patients. 
However, to date, no clinical responses have been observed in RCC. 
The injection of the HLA-B7 gene into the tumors of 14 RCC patients 
by Dr. Nicholas Vogelzang and colleagues resulted in HLA-B7 RNA 
and protein expression in the majority of tumor samples. Although 
tumor infiltration by CD8+ T cells indicated induction of a cellular 
immune response, no clinical responses were observed (53). A recent 
Phase II study involving 25 patients has likewise failed to demonstrate 
clinical efficacy, These studies have indicated, however, the overall 
safety and feasibility of intralesional HLA-B7 gene transfer.
Monoclonal Antibodies
The role of mAbs in the treatment of metastatic RCC is evolving. 
mAbs that bind to tumor-specific antigens can be used for imaging or 
to deliver cytotoxic agents (/>., toxins or radioisotopes) to the tumor 
with greater specificity than any other anticancer agent. Therapeutic 
mAbs have demonstrated clinical efficacy in colon cancer and non- 
Hodgkin’s lymphoma (71, 72). In addition, mAbs are a powerful tool 
for identification of tumor antigens that may potentially be exploited 
as vaccines.
Recently, a RCC-specific antigen, the G250 antigen, was identified 
and has been cloned (73). The G250 antigen shows homology with a 
recently cloned cervical carcinoma-associated protein known as MN.
Studies are underway to establish whether G250 is immunogenic and 
has potential for use as a RCC vaccine.
The anti-G250 mAb (mG250) is a murine immunoglobulin-G, 
antibody that reacts with 85% of all RCC cell lines, all clear cell 
RCCs, and the majority of non-clear cell RCCs but does not react with 
normal kidney cells. According to Dr. Neil H. Bander, the 13^-labeled 
mG250 has considerable potential for imaging RCC and has proven to 
be more sensitive than conventional imaging techniques (74). The 
anti-G250 mAb may also have therapeutic potential. In a Phase II 
study investigating the therapeutic use of 13 ^-labeled mG250, 3 of 15 
treated patients achieved a partial response (54). More recently, a 
chimeric (humanized) mG250 has been developed and is currently 
being tested in clinical trials to determine its therapeutic potential. The
I ^  |
I-labeled chimeric mG25G has demonstrated a high level of tumor 
uptake with no immunogenicity (75). Therefore, it is a promising 
vehicle for delivery of cytotoxic levels of radiation to renal tumors.
Tumor-specific Vaccines
The first step in developing antitumor vaccines is the identification 
of RCC-specific tumor antigens that can also be used in vitro to 
generate CTLs with increased antitumor reactivity (76). Peptide map­
ping and mutagenesis techniques can then be brought to bear to 
enhance the immunogenicity of a putative tumor-associated antigen.
The G250 antigen was identified by generating mAbs to RCC cell 
lines, Dr, Benoit van den Eynde et a l  have also identified a putative 
RCC-specific antigen by expression cloning techniques. The antigen, 
designated RAGE for renal tumor antigen, stimulated autologous 
CTLs when expressed by transfected COS cells in the context of 
HLA-B7. Further analysis defined the antigenic peptide. Unfortu­
nately, this RCC-specific renal tumor antigen is only expressed by 
approximately 2% of freshly isolated RCC tumors and approximately 
40% of RCC cell lines. Therefore, its utility as a vaccine may be 
limited.
The identification of tumor-specific peptide antigens will play an 
important role in developing tumor vaccines but will require further 
study. The goals of this research are to elucidate the individual 
immune responses of cancer patients, identify tumor antigens, and 
isolate peptide antigens that will elicit a strong cellular immune 
response in the context of defined MHC class I antigens. Dr. Corne­
lius Melief described experiments examining the impact of the MHC 
class I binding stability on the immunogenicity of peptide antigens. 
The goal of this research is to define the parameters that define the 
most antigenic peptides (39).
Therapeutic Challenges and the Host Immune Response
Tumor physiology, multidrug resistance, and defects in the host 
immune response present challenges to successful therapy for RCC. 
On the third and final day of the symposium, Dr. Rakesh Jain 
presented an overview of renal tumor physiology and described fac­
tors such as heterogeneity in tumor blood flow, intratumor pressure, 
and leukocyte-endothelial interactions within tumor vasculature that 
may affect the efficacy of various therapeutic modalities. For exam­
ple, factors that affect the ability of leukocytes to bind to tumor 
vascular endothelium and extravasate can complicate cell-mediated 
modalities. A better understanding of these factors could facilitate 
improvements in future therapeutic strategies.
Deficiencies in T-cell signaling may play a role in the poor antitu­
mor immune response observed in mice bearing renal tumors. The 
relationship between functional deficits in the immune response and 
signaling molecules such as N F kB was addressed by Dr. James Finke. 
One hypothesis is that renal tumors secrete soluble factors that inhibit 
the nuclear translocation of the RelA/NF/cBl protein complex, which
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may contribute to poor T-cell activation. This could explain the 
deficient IL-2 and IL-2 receptor a  expression that has been observed 
in RCC tumor beds. Further research will be necessary to identify 
soluble factors responsible for this effect.
Conclusions
The successful treatment of metastatic RCC poses a significant 
therapeutic challenge. Because of the intrinsic multidrug resistance of 
renal cells, chemotherapy has proven ineffective. Immunotherapy 
with rIL-2 is the current standard for treating RCC, and a number of 
promising new immunotherapeutic strategies are currently under in­
vestigation. Although none have demonstrated clear superiority over 
rIL-2 therapy, some combination regimens and adoptive immunother­
apy strategies may improve response rates and prolong survival with 
less morbidity than single-agent rIL-2 therapy. Reducing the toxicity 
of therapy is important, particularly for immunocompromised pa­
tients. Particularly promising are strategies to improve the antitumor 
activity of adoptively transferred leukocytes using cytokine priming, 
dendritic cells, or genetic manipulation. Research aimed at defining 
the clinical parameters that can predict responses to immunotherapy is 
also beginning to bear fruit.
Perhaps the most potent weapon that we can yield against RCC is 
a tumor vaccine that will mobilize an effective in vivo, cellular, 
antitumor, immune response. Currently, tumor cell vaccines using 
genetically altered tumor cells are in the early stages of clinical 
testing, and researchers are experimenting with direct intralesional 
DNA transfer to deliver genes to tumor cells. Recent advances in the 
identification of tumor-associated antigens have improved the pros­
pects for developing effective RCC-specific peptide vaccines and led 
to the development of RCC-specific mAbs with therapeutic potential.
Continued preclinical and clinical research will undoubtedly lead to 
a better understanding of the factors critical to induction of an effec­
tive antitumor immune response, which may involve overcoming 
functional deficits in the host immune ceils. This research, together 
with recent and continued advances in our understanding of the 
molecular genetics of RCC, will be critical to the development of a 
comprehensive strategy for treating this disease.
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